Earnings Date: July 28, 2026 (After Market Close) | Conference Call: July 29, 2026 at 10:00 AM ET Prepared: July 28, 2026
Key Takeaway: Setup is modestly constructive — consensus is a manageable bar after post-Q1 estimate resets, but the single biggest swing factor is the magnitude of property cat rate declines at mid-year renewals and their impact on net premiums written.
Heading into Q2 2026, the consensus bar for ACGL looks achievable: operating EPS of ~$2.47 and net premiums written of ~$4.22B represent a modest step-down from Q1's $2.50 EPS beat, and management's own commentary at Q1 earnings telegraphed continued competitive headwinds in property cat and flat-to-declining top-line growth in insurance. Management's tone since last earnings has been cautiously disciplined — the company confirmed at Q1 that mid-year property cat renewals (6/1 and 7/1) would remain competitive, with double-digit rate declines expected, and that the operating expense ratio would remain elevated in Q2 before normalizing in H2; both of these are already embedded in consensus. Estimate revisions have drifted modestly lower since the Q1 print (Q2 EPS consensus slipped from $2.41 to $2.47 on a net basis, with FY 2026 EPS trimmed from $9.35 to $9.28), suggesting the street has already absorbed the top-line headwinds. The stock has recovered sharply from its post-Q1 sell-off (down ~5% on April 29) and is now up ~7% since last earnings, outperforming the insurance ETF (IAK, +12%) and broadly in line with the S&P 500 (+4%), implying the market has partially re-rated the stock on capital return optionality rather than premium growth. The key wildcard is Iran conflict losses — management guided to additional Q2 losses from political violence and war-on-land lines out of London, and the size of that charge relative to the cat load will be the primary source of EPS surprise in either direction.
Key Takeaway: Consensus is a low-to-moderate bar on EPS (street already pricing in rate headwinds and elevated expenses), but net premiums written is the bigger swing factor — any upside surprise there would signal better-than-feared mid-year renewal outcomes and likely drive the stock.
KPI | Q2 2025 Actual (Prior Year) | Q1 2026 Actual (Last Quarter) | Q2 2026 Consensus Estimate | YoY Change | Guidance / Mgmt Commentary | Consensus vs. Guidance |
EPS — Diluted Operating ($) | $2.58 | $2.50 | $2.47 | -4.3% YoY | No explicit Q2 guidance; mgmt flagged elevated OpEx in Q2 before H2 normalization | N/A — no numeric guidance |
Net Premiums Written ($B) | $4.35B | $4.35B | $4.22B | -3.0% YoY | Mgmt guided ~$250M NPW headwind from MCE non-renewals throughout 2026; mid-year cat renewals expected competitive | Consensus below implied run-rate; reflects rate declines + MCE drag |
Combined Ratio — Ex-Cat, Ex-PYD (%) | 80.8% | 82.4% | 82.2% | +140 bps YoY | Mgmt: rates just below trend; margins sustainable near-term; OpEx elevated in Q2 | Consensus roughly in line with mgmt tone |
Underwriting Income ($M) | $818M | $728M | $689M | -15.8% YoY | No explicit guidance; Q1 was impacted by MCE transition costs; Q2 still elevated | Consensus below Q2 2025 actual; reflects competitive market |
Net Investment Income ($M) | $405M | $408M | $425M | +5.0% YoY | ~$48B portfolio; short duration; mgmt expects modest sequential improvement | Consensus above Q1 actual; modest tailwind expected |
Operating ROE (%) | 18.2% | 15.4% | 15.0% | -320 bps YoY | Mid-teens ROE target; mgmt building excess capital for return | Consensus in line with mgmt mid-teens framing |
Book Value Per Share ($) | $59.17 | $66.19 | $68.16 | +15.2% YoY | Mgmt repurchased $783M in Q1; $311M additional in Q2 through late April; $6B total authorization | Consensus implies continued BVPS growth despite buybacks |
Sources: Visible Alpha consensus and actuals data. All consensus figures as of latest available (July 2026).
KPI 1: EPS — Diluted Operating ($)
Quarter | Reported | Consensus | Surprise % | Result |
Q1 2026 | $2.50 | $2.45 | +2.0% | Beat |
Q4 2025 | $2.98 | $2.54 | +17.3% | Beat |
Q3 2025 | $2.77 | $2.18 | +27.1% | Beat |
Q2 2025 | $2.58 | $2.32 | +11.2% | Beat |
Q1 2025 | $1.54 | $1.31 | +17.6% | Beat |
Q4 2024 | $2.26 | $1.87 | +20.9% | Beat |
Q3 2024 | $1.99 | $2.00 | -0.5% | In-Line / Slight Miss |
Q2 2024 | $2.57 | $2.21 | +16.3% | Beat |
KPI 2: Net Premiums Written ($B)
Quarter | Reported ($B) | Consensus ($B) | Surprise % | Result |
Q1 2026 | $4.35B | $4.50B | -3.4% | Miss |
Q4 2025 | $3.65B | $3.96B | -7.8% | Miss |
Q3 2025 | $3.96B | $4.40B | -9.9% | Miss |
Q2 2025 | $4.35B | $4.30B | +1.2% | Beat |
Q1 2025 | $4.52B | $4.78B | -5.5% | Miss |
Q4 2024 | $3.82B | $3.92B | -2.5% | Miss |
Q3 2024 | $4.05B | $3.83B | +5.7% | Beat |
Q2 2024 | $3.78B | $3.94B | -4.1% | Miss |
Pattern: ACGL has beaten EPS consensus in 7 of the last 8 quarters with an average beat of ~14%, reflecting consistently conservative street estimates; however, net premiums written has missed consensus in 6 of the last 8 quarters as the market has been slow to reset top-line expectations for the competitive rate environment — this persistent NPW miss pattern means the bar on premiums is now more appropriately set heading into Q2 2026. Source: Visible Alpha consensus and actuals data.
Key Takeaway: No formal numeric guidance was revised post-Q1 earnings, but management's tone has shifted toward capital return as the primary near-term priority as reinsurance growth has tapered materially; the $3B buyback authorization increase and $311M of Q2 repurchases already executed are the most important post-earnings development.
Metric | Initial Guidance (Q1 2026 Earnings Call, Apr 28) | Revised Guidance | Current Consensus | Note |
Operating EPS (Q2 2026) | No explicit guidance; mgmt flagged elevated OpEx in Q2 before H2 normalization | — | $2.47 | No post-earnings revision; consensus drifted slightly lower post-Q1 print |
Net Premiums Written (Q2 2026) | ~$250M NPW headwind from MCE non-renewals throughout 2026; mid-year renewals expected competitive with double-digit cat rate declines | — | $4.22B | RNR Q2 2026 results confirmed property cat rates down high-teens at mid-year — consistent with ACGL guidance |
Operating Expense Ratio | Elevated in Q2 due to MCE systems cutover costs; expected to normalize toward historical levels in H2 2026 | — | 82.2% ex-cat ex-PYD combined ratio (consensus) | Q2 still expected to carry transition costs; H2 normalization is the key margin catalyst |
Share Repurchases | $783M repurchased in Q1; Board authorized additional $3B (total $6B authorization); $311M repurchased in Q2 through April 29 | — | N/A — not in VA consensus | Capital return is front and center; mgmt confirmed no structural limits to returning all or more than operating income |
Property Cat PML | Peak zone PML flat at $1.9B (8.2% of tangible equity) at 4/1; more meaningful changes expected at 6/1 and 7/1 depending on rate outcomes | — | N/A | 7/1 renewal outcomes will be disclosed on Q2 call; key read on cat exposure trajectory |
Iran Conflict Losses | Additional Q2 losses expected from political violence, war-on-land, terror lines out of London; Q1 losses absorbed within cat load | — | N/A — not in VA consensus | Key wildcard for Q2 EPS; industry loss estimated at several billion dollars; Arch selectively wrote incremental business at spiked rates |
MidCorp (MCE) Growth | Systems migration complete; core upper middle market business stabilizing; meaningful growth contribution is a 2027 story | — | N/A | No change to tone; Q2 will still reflect MCE non-renewal drag (~$250M annualized) |
Key Takeaway: Estimates for Q2 2026 and FY 2026 have drifted modestly lower since the Q1 print, with EPS trimmed ~2% and NPW down ~1% — revisions are tracking management's cautious tone on top-line growth, and the gap between consensus and guidance is not a meaningful risk or cushion in either direction.
KPI (Period) | Estimate (May 5, 2026 — 5 Days Post Q1 Print) | Current Consensus | Estimate Δ (%) | Initial Guidance (Q1 Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
EPS — Diluted Operating (Q2 2026) | $2.41 | $2.47 | +2.5% | No explicit guidance | No explicit guidance | N/A | N/A |
EPS — Diluted Operating (FY 2026) | $9.35 | $9.28 | -0.7% | No explicit guidance | No explicit guidance | N/A | N/A |
Net Premiums Written (Q2 2026) | $4.27B | $4.22B | -1.3% | ~$250M NPW headwind from MCE non-renewals in 2026; mid-year cat rates expected competitive | Unchanged | Flat | Consensus below guidance-implied run-rate; reflects rate declines |
Net Premiums Written (FY 2026) | $16.26B | $16.17B | -0.6% | ~$250M NPW headwind from MCE non-renewals in 2026 | Unchanged | Flat | Consensus tracking guidance |
Combined Ratio Ex-Cat Ex-PYD (Q2 2026) | 82.1% | 82.2% | +0.1 pts | Elevated OpEx in Q2; normalization in H2 | Unchanged | Flat | Consensus in line with mgmt tone |
Underwriting Income (Q2 2026) | $655M | $689M | +5.2% | No explicit guidance | No explicit guidance | N/A | N/A |
Estimates have been modestly revised upward for Q2 EPS (+2.5%) since the post-Q1 baseline, likely reflecting the strong capital return signal from the $3B buyback authorization, while FY 2026 EPS has been trimmed slightly (-0.7%) as analysts reset for the full-year top-line headwinds. The revision trajectory is orderly and not signaling a material risk in either direction. Source: Visible Alpha consensus and actuals data.
Key Takeaway: ACGL has recovered from its post-Q1 sell-off and is up ~7% since last earnings, but has meaningfully underperformed the insurance ETF (IAK, +12%) — the gap reflects the market rewarding peers with cleaner top-line growth stories while ACGL's premium headwinds weigh on sentiment despite strong EPS and capital return.
Sector ETF used: IAK (iShares U.S. Insurance ETF) — appropriate for ACGL's P&C insurance and reinsurance sub-sector. ACGL is a top holding in IAK. The S&P 500 (SPY) is included as the broad market benchmark.
ACGL vs IAK (Insurance ETF) vs S&P 500 — Indexed to 100 at April 28, 2026 (Last Earnings Date). Source: Stock Price Data.
Performance Summary (April 28 – July 28, 2026): ACGL opened at $97.06 on earnings day (April 28), fell to $92.72 on April 29 (-4.5% day-after reaction), and has since recovered to $103.88 as of July 28 (+7.0% total since last earnings). IAK gained +11.8% over the same period, and SPY gained +3.9%. The stock's underperformance vs. IAK is notable — peers with cleaner premium growth stories (RNR, HG) have been rewarded more. Key events marked: leadership restructure announcement (June 3), $2B debt offering completion (June 9), and Halgan/Schmeiser CEO appointments (June 17). The stock re-rated higher in late June/early July, likely driven by the leadership clarity and the broader insurance sector rally. The stock is now trading at approximately
Valuation context: At ~$104, ACGL trades at approximately 11x NTM operating EPS ($9.28 consensus), a discount to its historical average of ~13-14x and to peers like RNR (~12x). The discount reflects market skepticism on premium growth sustainability, but the aggressive buyback program (which is accretive to EPS and BVPS) provides a floor. The stock is not pricing in a beat — it is pricing in execution on capital return.
Key Takeaway: Peer commentary from Q2 2026 reporters (RNR) and Q1 2026 reporters commenting on Q2 outlook (HG, SPNT) paints a consistent picture: property cat rates down high-teens at mid-year, casualty reinsurance under ceding commission pressure, and cyber softening — all headwinds ACGL has already flagged, suggesting consensus is appropriately calibrated. The positive read-through is that underlying underwriting margins remain adequate and benign cat activity is a tailwind.
Note: Only commentary about Q2 2026 market conditions or forward-looking statements made after Q1 2026 earnings is included below. Q1 2026 results commentary (i.e., peers discussing their own Q1 performance) is excluded.
Most directly relevant peer: RNR is a pure-play reinsurer with significant property cat and casualty reinsurance exposure, making it the highest-quality read-through for ACGL's reinsurance segment.
Relevant for: ACGL's property reinsurance and specialty insurance segments; HG is a Bermuda-based specialty insurer/reinsurer with overlapping lines.
Relevant for: ACGL's specialty insurance and reinsurance segments; SPNT is a smaller specialty reinsurer with overlapping casualty and property lines.
Theme | Peer Signal | ACGL Implication | Direction |
Property Cat Rates at Mid-Year | RNR: down high-teens; HG: "more of the same"; SPNT: down ~15% | Consistent with ACGL Q1 guidance; no incremental negative surprise | Neutral |
Cat Activity (Q2 2026) | RNR: strong combined ratio of 72.8%; low cat losses; SPNT Q1: benign cat | Positive read for ACGL Q2 cat load; supports EPS beat potential | Positive |
Casualty Reinsurance / Ceding Commissions | RNR: increased cession rates; casualty GPW down 15%; HG: sidecar launched | Confirms ceding commission pressure; ACGL's casualty reinsurance NPW likely under pressure | Negative |
Casualty Sidecar Market Impact | RNR: impact "negligible" so far; HG: launched $300M sidecar | Near-term headwind confirmed but not yet market-moving; ACGL's concern is valid but not acute | Neutral |
Cyber Rate Pressure | RNR: explicit rate pressure in cyber; SPNT: competitive financial/professional lines | Consistent with ACGL's mid-cycle caution on cyber; no incremental surprise | Neutral |
E&S Casualty Growth | HG Select: +17% E&S casualty; SPNT: excess casualty still double-digit rate increases | Positive read for ACGL's E&S casualty and specialty lines; growth opportunity intact | Positive |
Iran/Middle East Losses | HG: manageable exposure; losses in political violence/terror/marine out of Lloyd's | ACGL's Q2 Iran losses likely concentrated in London specialty book; HG's manageable exposure suggests no systemic industry shock | Neutral / Watch |
Prior Year Development | RNR: $199M favorable PYD in property; $58M adverse in casualty (incl. Baltimore Bridge) | Favorable property PYD environment is a positive read; Baltimore Bridge adverse development is a watch item for ACGL's specialty book | Mixed |
Key Takeaway: The most important development since Q1 earnings is the leadership restructuring and CEO appointments (June 17) — elevating segment-level CEOs signals Arch is building for scale in reinsurance and mortgage, and the market reacted positively. The $2B debt offering is a secondary but meaningful capital structure event.
Key Takeaway: No open-market buys or discretionary sells by senior executives or the CEO/CFO since last earnings — the only notable transaction is a director open-market purchase of $5,300 by Daniel Houston on April 30 (the day after the post-earnings sell-off), which is a modest but directionally positive signal. All other transactions are routine director compensation awards or a gift/transfer by the Chairman.
Name | Title | Transaction Type | Value / Shares | Transaction Date | Note |
Houston, Daniel Joseph | Director | Open Market Buy | 5,300 shares (~$493K at ~$93/share) | April 30, 2026 | Discretionary purchase the day after post-Q1 sell-off; directionally positive signal |
Pasquesi, John M. | Chair, Director | Gift / Transfer (Code G) | ~$1.007M (gift from LLC to Trust) | June 11, 2026 | Internal transfer between related entities (LLC to Trust); not an open-market sale; no economic change in beneficial ownership |
Posner, Brian S. | Director | Open Market Sale (Preferred Shares) | 3,000 Depositary Shares, Series F | June 3, 2026 | Sale of preferred depositary shares (not common equity); limited read-through to common stock outlook |
Posner, Brian S. | Director | Open Market Sale (Preferred Shares) | 2,000 Depositary Shares, Series G | May 11, 2026 | Sale of preferred depositary shares (not common equity); limited read-through to common stock outlook |
Multiple Directors (8 individuals) | Directors | Compensation Award (Code A) | 2,071–3,398 shares each (routine annual director equity grants) | May 5, 2026 | Routine annual director compensation awards; not open-market purchases; no signal value |
Summary: Insider activity since last earnings is largely routine (director compensation awards, a gift/transfer by the Chairman, and preferred share sales by one director). The only open-market common equity purchase is Director Houston's $493K buy on April 30 — the day after the post-Q1 sell-off — which is a modest positive signal. No senior management (CEO, CFO, President) transactions are present in the period. The absence of executive selling is neutral-to-positive. No 10b5-1 plan initiations were disclosed in the period.
Source: Insider Transaction Data (SEC Form 4 filings, April 28 – July 28, 2026).